BicycleTx Limited

BCYC · Nasdaq · United Kingdom

Share price · BCYC

$3.11-0.88 (-22.06%) 3M

close as of 2026-11-18 · 24h delayed · vol 568K (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BCYC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Oct 2026+18.6%
  2. 2 Oct 2026-5.1%
  3. 24 Jul 2026-7.0%
  4. 10 Jul 2026+5.5%
  5. 21 Apr 2026-6.8%
  6. 1 Apr 2026+5.6%
  7. 24 Mar 2026+3.7%
  8. 18 Mar 2026-7.3%
  9. 13 Mar 2026-5.2%

    Nothing announced by BCYC that day or the session before.

  10. 3 Feb 2026-7.6%

Share of unusual movement by asset

For each asset, the share of BCYC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zelenectide pevedotin
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—18%
Other company news (earnings, financing, releases naming no asset)—10%
Sessions with no dated event—72%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
EphA2Peptide
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Phase 2
Nectin-4Peptide
Bladder / Urothelial Cancer
Urothelial Carcinoma

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Nuzefatide pevedotinPhase 1/2Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer …
Est. primary completion 2026-12-31 · NCT04180371 · CT.gov ↗
What to watch
2027 (1)
January 2027 (1)
Zelenectide pevedotinPhase 1/2Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive …
Est. primary completion 2027-01 · NCT04561362 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
Zelenectide pevedotinPhase 2Metastatic Urothelial Cancer
Est. primary completion 2028-03 · NCT06225596 · CT.gov ↗
What to watch
June 2028 (1)
Zelenectide pevedotinPhase 2Breast Cancer
Est. primary completion 2028-06-30 · NCT06840483 · CT.gov ↗
What to watch
August 2028 (1)
Zelenectide pevedotinPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-08-31 · NCT06933329 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Nuzefatide pevedotinPhase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Est. primary completion 2029-03 · NCT07450859 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Nuzefatide pevedotin + Zelenectide pevedotinPhase 2Advanced Solid Tumors
Est. primary completion 2030-05-30 · NCT07681674 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 January 2025Topline resultZelenectide pevedotinUpdated Duravelo-1 topline data for zelenectide pevedotin plus pembrolizumab

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$34M$33M$470M$10M-$40M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.6M$41M$510M$50M-$50M operating cash flowreport ↗
2026-Q1$0.9M$49M$560M$61M-$66M operating cash flowreport ↗
2025-Q3$12M$58M$649M$59M-$71M operating cash flowreport ↗
2025-Q2$2.9M$71M$722M$79M-$73M operating cash flowreport ↗
2025-Q1$10.0M$59M$794M$61M-$86M operating cash flowreport ↗
2024-Q3$2.7M$48M$891M$51M-$40M operating cash flowreport ↗
2024-Q2$9.4M$40M$962M$40M-$45M operating cash flowreport ↗
2024-Q1$20M$35M$458M$27M-$71M operating cash flowreport ↗
2023-Q3$5.3M$40M$573M$50M-$1.0M operating cash flowreport ↗
2023-Q2$11M$40M$340M$43M$34M operating cash flowreport ↗
2023-Q1$4.9M$32M$294M$39M-$46M operating cash flowreport ↗
2022-Q3$3.0M$23M$361M$28M-$5.9M operating cash flowreport ↗
2022-Q2$4.4M$20M$373M$27M-$24M operating cash flowreport ↗
2022-Q1$3.9M$14M$407M$28M-$26M operating cash flowreport ↗
2021-Q3$4.3M$11M$260M$15Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$73M$240M$629M$55M-$250M operating cash flowreport ↗

BicycleTx Limited reported revenue of $72.59M, up 105.8% YoY, R&D spend of $240.28M, up 38.9% YoY, cash and equivalents of $628.72M, and a net loss of $218.96M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$35M$173M$880M$42M-$165M operating cash flowreport ↗
2023-FY$27M$157M$527M$45M-$61M operating cash flowreport ↗
2022-FY$14M$82M$339M$28M-$86M operating cash flowreport ↗
2021-FY$12M$45M$439M$17M-$15M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 49 sales ($523K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-05Perry Jennifer Scott · Chief Operating OfficerOpen-market sale30$3.57$107Form 4
2026-10-05Perry Jennifer Scott · Chief Operating OfficerOpen-market sale326$3.78$1KForm 4
2026-10-05Thompson Travis Alvin · Chief Financial OfficerOpen-market sale79$3.57$282Form 4
2026-10-05Lee Kevin · director, CHIEF EXECUTIVE OFFICEROpen-market sale1,638$3.57$6KForm 4
2026-10-05Perry Jennifer Scott · Chief Operating OfficerOpen-market sale80$3.56$285Form 4
2026-10-05Hannay Michael Charles Ferguson · CHIEF PROD & SUPPLY CHAIN OFFOpen-market sale242$3.57$864Form 4
2026-10-05Skynner Michael · CHIEF SCIENTIFIC OFFICEROpen-market sale503$3.57$2KForm 4
2026-10-05Perry Jennifer Scott · Chief Operating OfficerOpen-market sale326$3.78$1KForm 4